BioLineRx Reports Year End 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/2/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Whirlpool to close Mexico plant, expects $165M restructuring cost
- Meta Platforms stock surges 8% on cloud business plans
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Wall Street ends choppy session lower as tech shares drop
BioLineRx (BLRX) PT Lowered to $2 at Maxim Group
March 6, 2018 1:21 PM ESTMaxim Group lowered its price target on BioLineRx (NASDAQ: BLRX) to $2.00 (from $3.00) while maintaining a Buy rating.
Analyst Jason McCarthy commented, "BiolineRx reported 4Q17 with a net loss of $7.4M and ended the period with $50M in cash on the balance sheet,... More
